Cannabis Bioscience International Holdings, Inc. (CBIH) stock
Close on Oct 19, 2026Market cap $2.33MP/E –Yield –
Cannabis Bioscience International Holdings, Inc. saw revenue fall 64.1% to $123.63K over the twelve months to Feb 28, 2026. At the latest close the market valued the company at $2.33M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Feb 28, 2026
Valuation
- Market cap
- $2.33M
- P/E ratio
- –
- Price to sales
- 18.81
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $123.63K
- Net income
- -$515.29K
- EPS, diluted
- -$0.00
- Book value per share
- -$0.00
- Diluted shares
- 11.63B
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 568,363,611
- Average volume (20 days)
- 38,846,811
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CBIH | S&P 500 | Difference | CBIH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | 0.0% | +3.4% | −3.4 pts | ||
| Year to date | -60.0% | +13.3% | −73.3 pts | ||
| 1 year | -60.0% | +16.6% | −76.6 pts | ||
| 3 years | -50.0% | +86.4% | −136.4 pts | -20.6% | +23.1% |
| 5 years | -93.3% | +81.9% | −175.2 pts | -41.8% | +12.7% |
| 10 years | -99.3% | +318.9% | −418.2 pts | -39.4% | +15.4% |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Cannabis Bioscience International filed with the SEC as exhibits to Form 8-K or 6-K
About Cannabis Bioscience International
Services-Commercial Physical & Biological Research
Cannabis Bioscience International Holdings, Inc. operates in the medicinal cannabis, clinical research, and cannabidiol sectors through three core business divisions. Through its Pharmacology University segment, the company provides multi-level education, instructional seminars, and training programs covering legal, medical, and operational aspects of cannabis. Under its Alpha Research Institute unit, it acts as a sponsor and contract research organization conducting clinical trials. Additionally, the company develops cannabidiol products under the VitaCookies brand. Its educational and scientific offerings serve healthcare professionals, attorneys, cannabis industry workers, entrepreneurs, and patients.
Company profile, executives and historyCannabis Bioscience International stock: common questions
What is Cannabis Bioscience International's stock price?
CBIH closed at $0.00 on Oct 19, 2026, up 33.33% on the day.
What is Cannabis Bioscience International's market cap?
Cannabis Bioscience International was worth $2.33M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is CBIH's P/E ratio?
Cannabis Bioscience International lost money over the twelve months to Feb 28, 2026 (diluted EPS -$0.00), so it has no meaningful P/E ratio.
How much revenue does Cannabis Bioscience International make?
Cannabis Bioscience International reported revenue of $123.63K for the twelve months to Feb 28, 2026, down 64.1% from a year earlier.
Does Cannabis Bioscience International pay a dividend?
No. Cannabis Bioscience International has not paid a cash dividend over the last twelve months.
How has CBIH stock performed over the past year?
Including dividends, CBIH returned -60.0% over the past year, against +16.6% for the S&P 500.
Who are Cannabis Bioscience International's competitors?
Companies most similar to Cannabis Bioscience International by business, industry and size include ABSI, ISPC, ONMD, IXHL, PHCI.
See a number that looks wrong?